Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom

T Dorai-John, C J Thomson, S G Amyes

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

The in vitro activity of moxifloxacin and comparator agents against respiratory isolates from a range of geographically distinct centres around the United Kingdom was investigated in the following study. Clinical isolates of Streptococcus pneumoniae (n = 257), Haemophilus influenzae (n = 399) and Moraxella catarrhalis (n = 253) were obtained between March 1998 and April 1999 from nine centres in the United Kingdom. Sensitivity was determined by testing each isolate for its minimum inhibitory concentration (MIC) by agar dilution. Against Streptococcus pneumoniae moxifloxacin and grepafloxacin were the most active (MIC90 = 0.25 mg/l). Trovafloxacin and sparfloxacin were the next most active (MIC90 = 0.5 mg/l) followed by levofloxacin and ciprofloxacin. MIC90 values of the six fluoroquinolones versus H. influenzae ranged from ciprofloxacin > levofloxacin. Against M. catarrhalis the lowest MIC90 was that of grepafloxacin at 0.0625 mg/l followed by moxifloxacin, sparfloxacin, levofloxacin and ciprofloxacin. Trovafloxacin demonstrated the highest MIC90 at 0.5 mg/l. These results demonstrate that moxifloxacin has superior in vitro activity against respiratory tract pathogens than any other comparator quinolones available for clinical use.
Original languageEnglish
Pages (from-to)19-24
Number of pages6
JournalJournal of chemotherapy (Florence, Italy)
Volume14
Issue number1
Publication statusPublished - 2002

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom'. Together they form a unique fingerprint.

Cite this